Abstract 2271
Background
No previous study has evaluated the prognostic value of coagulation factors in patients with early-stage natural killer/T-cell lymphoma (NKTCL). The aim of this study was to investigate the relationships between coagulation function and clinical response and prognosis in patients with early-stage NKTCL.
Methods
The data of patients with stage I/II NKTCL who were treated in Cancer Hospital, Chinese Academy of Medical Sciences from January 2008 to January 2019 were collected and studied retrospectively. Data included patients’ clinical characteristics and related indexes of coagulation function before treatment (preoperative activated partial thromboplastin time (APTT), prothrombin time (PT), prothrombin time activity (PTA), fibrinogen (FIB), international normalized ratio (INR), D-dimer, and platelet count (PLT)). The cut-off value was set as the median of pretreatment coagulation factors.
Results
A total of 159 patients with stage I/II NKTCL were included in this study. Abnormal coagulation function was found in nearly half of (49.69%) patients, and increased D-dimer(16.28%) and FIB(11.25%) were the most common abnormalities. Univariate analysis showed that increased D-dimer level (P < 0.001) and increased FIB level (P = 0.021) reduced complete remission (CR) rate. In addition to other prognostic factors including Eastern cooperative oncology group (ECOG) score≥2, B symptom, increased lactate dehydrogenase (LDH) level, increased D-dimer level was also demonstrated to be associated with the unfavorable progression-free survival (PFS) (P = 0.003) and overall survival (OS) (P = 0.002). Multivariate analysis indicated that increased D-dimer level was an independent factor for poor clinical response (P = 0.008), PFS (P = 0.021) and OS (P = 0.007).
Conclusions
Our study suggested that elevated pretreatment coagulation factors especially D-dimer and plasma FIB were unfavorable predictors for clinical response, OS and PFS in early-stage NKTCL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dong Mei.
Funding
The Cancer Foundation of China, Beijing Hope Marathon Project Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5683 - Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash: A phase II randomized double-blind, placebo-controlled study
Presenter: Naiyarat Prasongsook
Session: Poster Display session 1
Resources:
Abstract
5437 - Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: possible relationship with oral mucositis
Presenter: Luciana Corrêa
Session: Poster Display session 1
Resources:
Abstract
1483 - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
Presenter: Toshihide Yokoyama
Session: Poster Display session 1
Resources:
Abstract
2047 - Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): a pilot within the PROTECT study
Presenter: Jeroen Derksen
Session: Poster Display session 1
Resources:
Abstract
5984 - Clinical characteristics are associated with acupuncture treatment response for xerostomia in cancer patients
Presenter: Wenli Liu
Session: Poster Display session 1
Resources:
Abstract
2845 - Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia.
Presenter: Alannah Smrke
Session: Poster Display session 1
Resources:
Abstract
724 - Accuracy of distress thermometer to measure cancer-related mood disorders in Chinese patients with cancer
Presenter: Sudip Thapa
Session: Poster Display session 1
Resources:
Abstract
2357 - Modalities of biosimilar filgrastim use in clinical practice in >1000 patients receiving chemotherapy regimens with a rest period of ≤14 days: the TOPAZE study
Presenter: Jean Marc Phelip
Session: Poster Display session 1
Resources:
Abstract
1426 - The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin)
Presenter: Douglas Blayney
Session: Poster Display session 1
Resources:
Abstract
712 - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapy
Presenter: Hikmat Abdel-Razeq
Session: Poster Display session 1
Resources:
Abstract